8-K

Glucotrack, Inc. (GCTK)

8-K 2024-05-02 For: 2024-04-26
View Original
Added on April 12, 2026

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported): April 26, 2024

GLUCOTRACK,

INC.

(Exact name of registrant as specified in its charter)

Delaware 001-41141 98-0668934
(State<br> or Other Jurisdiction (Commission (IRS<br> Employer
of<br> Incorporation) File<br> Number) Identification<br> No.)
301<br> Rte 17 North, Ste. 800, Rutherford, NJ 07070
--- ---
(Address<br> of principal executive offices) (Zip<br> Code)

Registrant’s telephone number, including area code: (201) 842-7715

N/A

(Former name or former address, if changed since last report)

Securities

registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock GCTK The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item5.07 Submission of Matters to a Vote of Security Holders

On April 26, 2024, Glucotrack, Inc., a Delaware corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the following five proposals:

Proposal1 – 2024 Equity Incentive Plan

The Company’s 2024 Equity Incentive Plan was approved. The final results of the voting were as follows:

Votes For Votes Against Abstentions Broker Non-Votes
9,989,257 885,365 5,163,149 1,932,226

Proposal2 – Election of Directors

Dr. Robert Fischell, Luis Malave, Andrew Sycoff, Shimon Rapps, Allen Danzig, and Erin Carter were each elected to serve on the Board of Directors (the “Board”) for a one-year term that expires at the 2025 Annual Meeting of Stockholders, or until their earlier death, resignation or removal and their successors are elected and qualified. The final results of the voting were as follows:

Director Votes For Votes Against Abstentions Broker Non-Vote
Dr. Robert Fischell 10,793,666 134,682 5,109,423 1,932,226
Luis Malave 10,793,666 122,745 5,121,360 1,932,226
Andrew Sycoff 10,805,663 5,231,471 637 1,932,226
Shimon Rapps 10,786,853 5,231,531 19,387 1,932,226
Allen Danzig 10,793,726 122,685 5,121,360 1,932,226
Erin Carter 10,793,806 122,745 5,121,220 1,932,226

Proposal3 – Reverse Stock Split

The Company’s stockholders approved of an amendment to Article IV of the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.001 per share at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the Board (the “Reverse Stock Split”) and with such Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion. The final results of the voting were as follows:

Votes For Votes Against Abstentions Broker Non-Votes
17,094,412 779,366 96,219

Proposal4 – Ratification of Independent Registered Public Accountant

The Company’s stockholders ratified the previous appointment by the Audit Committee of the Board of Fahn Kanne & Co. as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2023. The final results of the voting were as follows:

Votes For Votes Against Abstentions Broker Non-Votes
17,831,735 114,935 23,327

Proposal5 – Frequency of Non-Binding Advisory Votes on Executive Compensation

The Company’s stockholders indicated, on an advisory basis, the preferred frequency of future non-binding advisory votes on the compensation of the Company’s named executive officers as follows:

Every<br> <br>One (1) Year Every<br> <br>Two (2) Years Every<br> <br>Three (3) Years Abstentions
2,213,593 531,688 8,138,410 5,154,080

In light of the foregoing, the Company currently intends to hold an advisory vote on the compensation of its named executive officers every three (3) years until the next required advisory vote on the frequency of holding the advisory vote on named executive officer compensation.

ITEM9.01 Exhibit

Exhibit<br> 104 Cover<br> Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:<br> May 2, 2024
GLUCOTRACK, INC.
By: /s/ Paul Goode
Name: Paul<br> Goode
Title: Chief<br> Executive Officer